Table 1.
Demographics and clinical characteristics of participants from the phase 3 SUNBEAM and RADIANCE studies who enrolled in the DAYBREAK open-label extension trial.
| Characteristic | Ozanimod 0.92 mg (N = 2257 a ) |
|---|---|
| Age, years | |
| Mean (SD) | 37.3 (9.1) |
| Sex | |
| Men | 755 (33.5) |
| Women | 1502 (66.5) |
| Race | |
| White | 2244 (99.4) |
| Black | 9 (0.4) |
| Asian | 1 (<0.1) |
| Other | 3 (0.1) |
| BMI, b kg/m2 | |
| Mean (SD) | 24.2 (4.7) |
| BMI category b | |
| <30 kg/m2 | 2022 (89.6) |
| Time since MS symptom onset, years | |
| Mean (SD) | 6.8 (6.2) |
| Concomitant SSRI/SNRI use | 274 (12.1) |
| Trazodone hydrochloride | 54 (19.7) c |
| Escitalopram | 52 (19.0) c |
| Sertraline hydrochloride | 49 (17.9) c |
| Escitalopram oxalate | 30 (11.0) c |
| Venlafaxine hydrochloride | 25 (9.1) c |
| Sertraline | 24 (8.8) c |
| Fluoxetine hydrochloride | 23 (8.4) c |
| Fluoxetine | 22 (8.0) c |
| Paroxetine | 22 (8.0) c |
| Venlafaxine | 16 (5.8) c |
| Duloxetine | 14 (5.1) c |
| Citalopram | 13 (4.7) c |
| Paroxetine hydrochloride | 12 (4.4) c |
| Citalopram hydrobromide | 11 (4.0) c |
| Duloxetine hydrochloride | 5 (1.8) c |
| Vortioxetine hydrobromide | 4 (1.5) c |
| Desvenlafaxine | 2 (0.7) c |
| Fluvoxamine maleate | 2 (0.7) c |
| Trazodone | 1 (0.4) c |
| Vortioxetine | 1 (0.4) c |
SD: standard deviation; BMI: body mass index; MS: multiple sclerosis; SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin–norepinephrine reuptake inhibitor.
Data are presented as n (%) at DAYBREAK baseline, unless otherwise indicated.
a
One participant did not receive study drug.
b
At parent study baseline.
c
Percentage based on participants on an SSRI/SNRI medication.